Utilizing Next Generation Sequencing to Evaluate Genomic Complexity in Thai Patients with Multiple Myeloma

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20211020003

Enrollment

Registered

2021-10-20

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The newly diagnose with MM The newly diagnose with plasma cell disorder Relapse MM patient Thai population Multiple Myeloma Next Generation Sequencing Somatic mutation

Interventions

The GeneRead QIAact Custom Panel (Qiagen, Hilden, Germany), Multiple Myeloma and Acute Lymphoid Leukemia pane covered somatic mutation in 59 targeted genes, was determine to perform on the QIAGEN Gene

Experimental Genetic

somatic mutation

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patient have never been diagnosed or treated with other malignancies before diagnosed with MM. 2. Patients should receive the treatment of multiple myeloma and the medical history must be recorded belong to Siriraj hospital.

Exclusion criteria

Exclusion criteria: Patient who cannot do bone marrow aspiration.

Design outcomes

Primary

Measure	Time frame
Mutated gene 12 month Next Generation Sequencing	—

Secondary

Measure	Time frame
N/A N/A N/A	—

Countries

Thailand

Contacts

Public ContactChutirat Jirabanditsakul

Division of Hematology, Faculty of Medicine Siriraj Hospital, Mahidol University

chutirat.jir@mahaidol.ac.th024194420

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026